Atossa Therapeutics (NASDAQ:ATOS) PT Raised to $6.50

Atossa Therapeutics (NASDAQ:ATOS) had its price target lifted by equities researchers at Ascendiant Capital Markets from $6.25 to $6.50 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price points to a potential upside of 333.33% from the stock’s current price.

ATOS has been the topic of a number of other research reports. StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Atossa Therapeutics in a report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th.

Atossa Therapeutics Stock Down 1.3 %

Atossa Therapeutics stock opened at $1.50 on Wednesday. Atossa Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.31. The stock has a market cap of $188.64 million, a P/E ratio of -6.25 and a beta of 1.19. The company’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts expect that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Therapeutics

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Atossa Therapeutics in the second quarter valued at approximately $29,000. Cetera Advisors LLC acquired a new position in Atossa Therapeutics in the 1st quarter valued at $72,000. Virtu Financial LLC bought a new position in Atossa Therapeutics in the 1st quarter worth $151,000. Rhumbline Advisers acquired a new position in Atossa Therapeutics during the 2nd quarter worth $161,000. Finally, Bank of New York Mellon Corp boosted its holdings in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after acquiring an additional 399,041 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.